Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXTEN-A: Safety and PK of BIVV001 in Severe Hemophilia A
NCT03205163Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2017
- Primary completion
- Nov 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, open-label trial of efanesoctocog alfa in hemophilia A (2 cohorts), sponsored by Sanofi. Primary endpoints: Treatment Emergent Adverse Events and Confirmed Inhibitor Development. Started Aug 2017; status: completed.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03205163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03205163.